Showing results (181-190 of 326) with videos related to

Sort By:
Pageof 33
Current Medical Research and Opinion|July 14, 2021
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myelomaTom Martin, Saad Z Usmani, Jordan M Schecter, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 28, 2022
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple MyelomaKatja Weisel, Amrita Krishnan, Jordan M Schecter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2013
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman diseaseRazelle Kurzrock, Peter M Voorhees, Corey Casper, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 1, 2023
A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First RelapseManisha Bhutani, David M Foureau, Myra Robinson, et al.
JAMA Oncology|June 18, 2026
Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-AnalysisJaromir Tomasik, Tobias Tix, Mohammad Alhomoud, et al.
The American Journal of Emergency Medicine|October 4, 2025
Using ice packing and the polar life pod to treat severe hyperthermiaKevin C Miller, Jessie L Beck, Sofia G Valadez, et al.
Ejhaem|July 18, 2022
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myelomaThomas Martin, Amrita Krishnan, Kwee Yong, et al.
Blood|July 5, 2019
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myelomaSaad Z Usmani, Hareth Nahi, Maria-Victoria Mateos, et al.
Leukemia & Lymphoma|April 5, 2018
Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myelomaAjai Chari, Sarah Larson, Beata Holkova, et al.
Journal of Cancer Research and Clinical Oncology|August 28, 2020
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial resultsSaad Z Usmani, Maria-Victoria Mateos, Vania Hungria, et al.
Pageof 33